LE
Lexaria Bioscience Corp.
LEXXW · NASDAQ
$0.01 +31.87% (+$0.00)
Market Cap $201.2K
P/E Ratio -
Div. Yield -
ROE 149.35%
Bulios Fair Price
$0
100.0% downside
Current Price
$0.012
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LEXXW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.04x
P/S 0.33x
P/FFO N/A
Growth
13 /100
Declining Book val. growth 6.43%
Rev. growth 10.43%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 1,850.10%
Gross margin 99.56%
FCF margin 1,586.10%
Quality
1 /100
Poor ROA 168.97%
ROIC 215.76%
Asset turnover 0.09x
Debt
100 /100
Low Net debt/EBITDA 0.40x
Debt/Equity 0.02x
Current ratio 3.90x
Stability
28 /100
Unstable EPS volatility 36.56%
Beta 0.37x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LEXXW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Richard C. Christopher
Employees
7
Headquarters
Kelowna